57 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
17 Jun 24
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
8:03am
Center in Rehovot, Israel. Dr. Oron stated, “I am pleased with the interim results of this innovative trial, demonstrating the safety of an AllocetraTM
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
14 Jun 24
Condensed Consolidated Financial Statements
4:30pm
medical needs,” as a stand-alone therapy or in combination with leading therapeutic agents.
We believe the Company’s primary innovative immunotherapy
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
3 Jun 24
Report of Foreign Private Issuer
8:05am
of osteoarthritis, and I believe that the unique and innovative mechanism of action of AllocetraTM may be a disease modifying treatment for these patients … for the development of an innovative tendon repair technique.
The investigator-initiated Phase I/II trial plans to recruit up to 46 patients
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
diseases, including sepsis, osteoarthritis and other inflammatory disorders.
We believe the Company’s primary innovative immunotherapy, AllocetraTM … innovative immunotherapy candidate, AllocetraTM, represents a paradigm shift in macrophage reprogramming, moving from a binary classification of M1 (pro
6-K
EX-99.1
79i1sdtg8t3y13la
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
EX-99.2
0nch19il3aug4cwh94
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
37hdum3wpg3s 5r2
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
tvyo1hdn
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
10qkc7vwf 15fxkcgu
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
7ni5jlrjaqev2 6vzs1i
31 May 23
Report of Foreign Private Issuer
8:09am
424B5
bv7b0xtp1s209d6tcdk5
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
hjhwrz1z66 qlmy9
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
d6zwpaarvmmd8m7x71
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
urg00y8
27 May 22
Condensed Consolidated Financial Statements
4:39pm
F-3
hfvxl 80ipda30
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.2
djsync73c dyll874
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
jsostmz0
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm